Investors

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

Investor Relations Home

Webcast ImageWebcast
Q4 2014 Portola Pharmaceuticals, Inc. Financial Results Conference Call  (Live)
03/02/15 at 5:30 a.m. PT
Q4 2014 Portola Pharmaceuticals, Inc. Financial Results Conference Call
Monday, March 2, 2015 5:30 a.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Portola Pharmaceuticals, Inc. at Cowen and Company 35th Annual Health Care Conference (Live)
03/03/15 at 8:40 a.m. ET
Portola Pharmaceuticals, Inc. at Cowen and Company 35th Annual Health Care Conference
Tuesday, March 3, 2015 8:40 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Stock Quote
PTLA (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$38.08
Change (%) Stock is Down 0.56 (1.45%)
Volume213,622
Data as of 02/27/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Corporate Profile

Portola Pharmaceuticals, Inc. was founded in 2003 and is headquartered in South San Francisco, Calif. We completed an initial public offering in May 2013 and are traded on the Nasdaq Stock Market under the symbol PTLA. We have approximately 95 employees.More >>

Recent NewsMore >>
DateTitle 
02/26/15Portola Pharmaceuticals Receives FDA Orphan Drug Designation for Andexanet Alfa, Its Breakthrough-Designated Factor Xa Inhibitor Antidote
-- Annually, Over 100,000 U.S. Patients Currently Impacted; Projected to Grow Up to 200,000 U.S. Patients by 2020 -- SOUTH SAN FRANCISCO, Calif., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that andexanet alfa, a U.S. Food and Drug Administration (FDA)-designated breakthrough therapy, has been granted orphan drug designation by the FDA's Office of Orphan Products Development for reversing the anticoagulant effect of direct or indirect Factor Xa inhibi... 
Printer Friendly Version
02/25/15Portola Pharmaceuticals to Present at the Cowen and Company 35th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3, 2015 at 8:40 a.m. Eastern Time in Boston. The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section. About Portola Pharmaceuticals, Inc. Portola P... 
Printer Friendly Version
02/24/15Portola Pharmaceuticals to Announce Fourth Quarter and Year End 2014 Financial Results and Host Conference Call on Monday, March 2
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter and year ended December 31, 2014, and provide a general business overview on Monday, March 2, 2015, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). Conference Call Details To access the live conference call, please dial (877) 280-4958 from the U.S. and Canada or +... 
Printer Friendly Version
02/09/15Portola Pharmaceuticals Appoints Two Biotechnology Industry Veterans, Laura Brege and Dr. Dennis Fenton, to Board of Directors
SOUTH SAN FRANCISCO, Calif., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced the appointment of Laura Brege and Dennis Fenton, Ph.D., to its board of directors. Ms. Brege serves as president and chief executive officer of Nodality, Inc., a life sciences company focused on innovative personalized medicine. Dr. Fenton is the owner and chief executive officer of Fenton and Associates, a biotechnology consulting firm. "Laura and Dennis have directly relevan... 
Printer Friendly Version
02/05/15Portola's Factor Xa Inhibitor Betrixaban Successfully Passes Futility Analysis in Phase 3 APEX Study; Trial Continues as Planned and Remains on Track for Enrollment Completion by Year-End
Betrixaban Has the Potential to be the First Approved Therapy for Hospital-to-Home Prevention of Fatal Blood Clots for the Over 20 Million High-Risk Acute Medically Ill Patients SOUTH SAN FRANCISCO, Calif., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that the Independent Data Monitoring Committee (IDMC) recommended that the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study of betrixaban continue as planned withou... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
03/02/15 5:30 a.m. PT
Q4 2014 Portola Pharmaceuticals, Inc. Financial Results Conference Call
03/03/15 8:40 a.m. ET
Portola Pharmaceuticals, Inc. at Cowen and Company 35th Annual Health Care Conference
LocationBoston, MA

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.